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Prohibitins (PHB1 and PHB2) are versatile proteins located at the innermitochondrial membrane,
maintaining normal mitochondrial function and morphology. They interact with the NADH dehy-
drogenase protein complex, which is essential for oxidoreductase activity within cells. However,
their expression in lung epithelium, especially in smokers and patients with inflammatory lung
diseases associated with increased oxidative stress, such as COPD, is unknown. Lung tissue spec-
imens from 45 male subjects were studied: 20 COPD patients [age: 65.7  5.8 years, smoking:
84.6  33.6 pack-years, FEV1 (%pred.): 58.7  14.6, FEV1/FVC (%): 63.8  9.4], 15 non-COPD
smokers [age: 59.0  12.1 years, smoking: 52.5  20.8 pack-years, FEV1 (%pred.): 85.5  14.2,
FEV1/FVC (%): 78.5  4.7] and 10 non-smokers. Quantitative real-time PCR experiments were
carried out for PHB1 and PHB2, using b-actin as internal control. Non-COPD smokers exhibited
lower PHB1 mRNA levels when compared to non-smokers (0.55  0.06 vs. 0.90  0.06,
PZ 0.043), while PHB1 expression was even further decreased in COPD patients (0.32  0.02),
a statistically significant finding vs. both non-COPD smokers (P Z 0.040) and non-smokers
(P < 0.001). By contrast, PHB2 levels were similar among the three study groups. Western blot
analysis for the PHB1 protein verified the qPCR results (non-smokers: 1.77  0.13; non-COPD
smokers: 0.97  0.08; COPD patients: 0.59  0.10, PZ 0.007). Further analysis revealed that
PHB1 downregulation in COPD patients cannot be attributed solely to smoking, and that PHB1
expression levels are associated with the degree of airway obstruction [FEV1 (PmRNAZ 0.004,
PproteinZ 0.014)]. The significant downregulation of PHB1 in COPD and non-COPD smokers in
comparison to non-smokers possibly reflects a distortedmitochondrial function due to decreased
mitochondrial stability, especially in the mitochondria of COPD patients.
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nents of the mitochondrial fusion machinery, maintainingChronic Obstructive Pulmonary Disease (COPD) is a multi-
factorial cigarette smoking related disorder. Its clinical
manifestations include chronic bronchitis, pulmonary
emphysema and small airway disease, all of which even-
tually lead to the progressive destruction of lung paren-
chyma and to deterioration of lung function. Several
mechanisms contribute to the pathogenesis of COPD,
including influx of inflammatory cells into the lung,
abnormal cellular growth, increased apoptotic events,
extracellular matrix destruction and oxidative stress.
Genetic background and infectious agents also play an
important role.1e3
External triggers such as tobacco smoke, noxious gases
and viruses initiate local inflammation in the lung,
enhancing oxidative stress. Reactive oxygen species (ROS)
cause functional and structural alterations affecting redox-
sensitive cellular processes such as mitochondrial
function.4
The formation of oxidants, which are also produced
within cells as by-products of normal metabolism, is
balanced by antioxidants, which delay or hinder the
oxidation process. A diverse group of molecules exhibit
antioxidant properties; ranging from small molecules such
as glutathione and vitamins C and E, to iron-binding protein
chains, to enzymatic systems such as catalases, peroxidases
and superoxide dismutases (SOD).5 These enzymes have
isoforms with specific distribution: extracellular, cytosolic
and particularly mitochondrial.6,7 Indeed, the majority of
ROS compounds are formed during oxidative phosphoryla-
tion at the mitochondrial electron transport chain.8
The eukaryotic mitochondrial prohibitin (PHB) family
comprises two members with w53% amino acid homology,
named prohibitin-1 (PHB1), a 30 kDa protein located at
17q21 and prohibitin 2 (PHB2 or REA), a 32 kDa protein
located at 12p13.9 Both are ubiquitously expressed in
eukaryotic cells, playing a significant role in several intra-
cellular processes such as transcription regulation,
apoptosis, cell cycle progression and aging,10e12 as well as
in many diseases like obesity, diabetes and cancer.13 Pro-
hibitins have been found in several cellular compartments,
such as the plasma membrane and the nucleus,14,15 but are
predominately localized in the inner mitochondrial
membrane.16 PHB1 and PHB2 form heterodimers, which are
the building blocks of large ring-shaped prohibitin
complexes, with diameter of w20e25 nm and >1 MDaTable 1 Anthropometric characteristics and spirometric values
COPD patients (n Z 20) Non-COPD sm
Age (years) 65.7  5.8 59.0  12.1
Smoking (P-Y) 84.6  33.6 52.5  20.8
FEV1 (% pred.) 58.7  14.6 85.5  14.2
FVC (% pred.) 73.4  15.3 86.1  12.7
FEV1/FVC (%) 63.8  9.4 78.5  4.7
P-Y: pack-years of smoking (mean  SD).
FEV1: forced expiratory volume in 1st second (mean  SD).
FVC: forced vital capacity (mean  SD).
a KruskaleWallis H test.molecular mass.17 These complexes are essential compo-
mitochondrial stability, morphogenesis and normal
function.18e20
Recent findings suggest that prohibitin plays an impor-
tant role in combating oxidative stress,13 by interacting
with the NADH dehydrogenase subunits of the mitochon-
drial respiratory complex I, acting as complex I assembly
chaperons.21 This has been observed in intestinal epithelial
cells,22 in endothelial cells,20 and in ex vivo rabbit lung
experiments.23 However, little is known about prohibitin
expression and function in human lung tissue.
To gain insight into the involvement of prohibitin in
redox changes associated with lung pathology, we deter-
mined the mRNA and protein levels of PHB1 and PHB2 in the
lung epithelium, particularly under high ROS-generating
conditions such as smoking, and in patients with inflam-
matory lung diseases associated with increased oxidative
stress such as COPD, and we associated their expression
with patients’ anthropometric and spirometric values.
Materials and methods
Study subjects
The study was performed on lung tissue specimens from 45
male subjects who underwent open lung surgery for the
excision of malignant solitary pulmonary nodule. Subjects
were divided in three groups: a) 20 COPD current smokers,
according to GOLD criteria,24 b) 15 non-COPD current
smokers and c) 10 non-smokers.
Smokers were defined as subjects who had a history of at
least 20 pack-years of cigarette smoking. All subjects
underwent routine pulmonary function testing. The GOLD
spirometric classification of COPD severity, based on post-
bronchodilator FEV1 was used for the diagnosis of COPD. All
COPD patients that participated in this study were GOLD
stage II (FEV1/FVC < 0.70, with 50%  FEV1 < 80% pre-
dicted) (Table 1).
The study was approved by the Medical Research Ethics
Committee of the University Hospital of Heraklion and
informed consent was obtained from all participants.
Tissue preparation
Human lung tissue samples were collected from all subjects
from an uninvolved segment of the subpleural parenchymaof COPD patients, non-COPD smokers and non-smokers.
okers (n Z 15) Non-smokers (n Z 10) P-valuea
58.5  12.1 0.065
e 0.002
105.3  8.5 <0.001
112.0  14.0 0.006
79.3  3.2 <0.001
956 N. Soulitzis et al.at least 5 cm away from the solitary nodule. Samples were
immediately frozen in liquid nitrogen and stored at 80 C
until use.
RNA extraction and cDNA preparation
Lung tissue specimens (w100 mg) were homogenized in
TRIzol reagent (Invitrogen, Carlsbad, CA) using a power
homogenizer and incubated at room temperature, followed
by the addition of chloroform and centrifugation. Total RNA
was precipitated from the supernatant with isopropanol,
washed with 75% ethanol and resuspended in 20 ml of DEPC-
treated water. RNA concentration and purity were calcu-
lated after measuring on a NanoDrop 1000 spectropho-
tometer (NanoDrop Products, Wilmington, DE) its 260 nm
absorbance and 260/280 nm and 260/230 nm absorbance
ratios, respectively. Representative samples were also run
on agarose gels, in order to verify that RNA was not
fragmented.
cDNA was synthesized by reverse transcription (RT) with
the RETROscript Kit (Ambion, Austin, TX), using random
decamers as amplification primers. In detail, 2.5 mg of total
RNA and 5 mM of random decamers were heated at 80 C for
3 min, in order to remove RNA secondary structures, and
placed on ice until the addition of cDNA synthesis mix,
which contained 1 RT Buffer, 0.5 mM dNTPs Mix, 10 un¡ts
RNase Inhibitor and 100 units MMLV-RT reverse transcrip-
tase. The final mix (volume 20 ml) was incubated at 55 C for
1 h. The reaction was terminated by heating at 92 C for
10 min and cDNA was stored at 20 C until use.
Quantitative real-time polymerase chain reaction
assay
PHB1 and PHB2 mRNA expression was measured using
a real-time qPCR assay with the SYBR Green I dye. A
housekeeping gene, beta-actin (b-actin), was used as an
internal control, in order to normalize PHB1 and PHB2
mRNA expression levels. The mRNA-specific primers, which
were designed with the Lasergene 7.0 software (DNASTAR,
Madison, WI) and span at least one intron with an average
length >800 bp, are listed in Table 2. After initial experi-
ments, in order to optimize the concentration and
annealing temperature of the primers, cDNA from all study
subjects (1 ml) was amplified in a PCR reaction containing
2 Maxima SYBR Green qPCR Master Mix (Fermentas, Glen






PHB1 GCG TGG TGA ACT CTG CCT TA 124
TGT ACC CAC GGG ATG AGA AA
PHB2 CCG AGG GCC TTC ACT TCA 91
CCT GTA GGG GAG GAG ATT TTT C
b-actin CGG CAT CGT CAC CAA CTG 70
GGC ACA CGC AGC TCA TTGprimer in a final volume of 20 ml. To ensure the accuracy of
the quantification measurements, a representative pool of
all samples was diluted in a series of six 2 dilutions and
was run on the same plate, in order to construct a standard
curve for the quantification process. After initial denatur-
ation at 95 C for 10 min, samples were subjected to 40
cycles of amplification, comprised of denaturation at 95 C
for 20 s, annealing at 60 C (b-actin) or 58 C (PHB1 and
PHB2) for 30 s and elongation at 72 C for 30 s, followed by
a melt curve analysis, in which the temperature was
increased from 60 C to 95 C at a linear rate of 0.2 C/s.
Data collection was performed during both annealing and
extension, with two measurements at each step, and at all
times during the melt curve analysis. PCR experiments were
conducted on an Mx3000P real-time PCR thermal cycler
using software version 4.10, Build 389 Schema 85 (Stra-
tagene, La Jolla, CA). Verification of the PCR products, in
terms of correct size and the absence of dimers, was con-
ducted using a 2% (w/v) agarose gel electrophoresis. After
amplification, standard curves were constructed from the
samples used in the series of consecutive dilutions. Subse-
quently, using these standard curves and the Ct value of the
samples, we calculated the mRNA expression of the genes
studied (Fig. 1). Samples with no amplification plots or with
dissociation curves that exhibited signs of primeredimer
formation or by-products were excluded. To normalize the
mRNA expression of each gene, its value was divided by the
same sample’s b-actin mRNA value. In each PCR reaction
two negative controls were included, one with no cDNA
template and one with no reverse transcription treatment.
All qPCR measurements were conducted in triplicates.
Protein extraction
Lung tissue samples (w100 mg) were dissolved in 2 ml of T-
PER Tissue Protein Extraction Reagent (Thermo Fisher
Scientific, Waltham, MA) with added HALT Protease and
Phosphatase Inhibitor Cocktails (Thermo Scientific) and
homogenized. After centrifugation at 10,000 g for 5 min
(Fig. 1) to pellet tissue debris, the supernatant was
collected and stored at 80 C until use.
Western blot
Western blot detection of PHB1 (30 kDa) and b-actin
(43 kDa), which was used as internal control, was per-
formed using standard protocols. Sample preparations of
each lung protein specimen (30 mg) were separated by
12.5% SDS-polyacrylamide gel electrophoresis, using b-
mercaptoethanol as reducing agent. The proteins were
then transferred electrophoretically from the gels to
a 0.45 mm nitrocellulose membrane (Thermo Scientific).
Membranes were incubated with 1 mg/ml of mouse anti-
PHB1 monoclonal antibody MS-261-P1ABX (Thermo Scien-
tific). After applying the AP124P goat anti-mouse peroxi-
dase conjugated secondary antibody (Millipore, Billerica,
MA), immunodetection was performed with the Super-
Signal West Pico Chemiluminescent Substrate (Thermo
Scientific), detected on Super RX X-ray films (Fujifilm,
Japan). The mouse anti-actin antibody MAB1501 (Millipore)
was used in order to normalize PHB1 protein expression.
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the Photoshop CS2 image analysis software (Adobe Systems,
San Jose, CA) (Fig. 1).
Statistical analysis
Prohibitin mRNA and protein levels were first evaluated by
the one-sample KolmogoroveSmirnov goodness-of-fit test,
in order to determine whether they follow a normal
distribution pattern. Depending on the results, Pearson’s or
the non-parametric Spearman’s rank correlation was used
to examine their association with continuous variables
(age, pack-years, spirometric values). Moreover, their
association with categorical data (smoking status) was
examined using Student’s t-test (after examining for
equality of variances with Levene’s test), or its non-
parametric equivalents ManneWhitney U and Krus-
kaleWallis H tests. Additionally, the Chi-square (c2) test,
replaced by Fisher’s exact test when indicated by the
analysis, was used to examine PHB1 and PHB2 expression
status with the various clinicopathological parameters after
stratification. Finally, univariate analysis was used to
correct crude p-values (Pc) for age and pack-years of
smoking, producing adjusted p-values (Pa). Statistical
analyses were 2-sided and performed with SPSS 11.5 (SPSS,
Chicago, IL). Statistical significance was set at the 95% level
(P < 0.05).Results
Clinical characteristics of the study groups
The anthropometric characteristics and spirometric values
of the three study groups (non-smokers, non-COPD smokers
and COPD smokers) are shown in Table 1. As expected from
the selection criteria, smokers with COPD had a signifi-
cantly lower value of FEV1, FVC and FEV1/FVC ratio thanFigure 1 Representative examples of quantitative real-time PCR
(B) Dissociation curves of PHB1 and PHB2; (C) Representative exam
after electrophoresis in a 2% (w/v) agarose gel and staining with
examples of prohibitin-1 Western blot analysis in non-smokers (NS),
used as internal control.non-COPD smokers (PFEV1 Z 0.001, PFVC Z 0.039,
PFEV1=FVC < 0.001, respectively). In contrast, smoking
exposure was higher in COPD patients versus non-COPD
smokers (84.6  33.6 pack-years vs. 52.5  20.8 pack-
years, P Z 0.012). Finally, although non-COPD smokers
were on averagew7 years younger than COPD smokers, this
age difference was not statistically significant (P Z 0.11)
Table 1.
Quantitative real-time PCR analysis
Non-COPD smokers exhibited lower PHB1 mRNA levels when
compared to non-smokers (0.55  0.06 vs. 0.90  0.06,
Pc Z 0.011, Pa Z 0.043), while PHB1 expression was even
further decreased in COPD patients (0.32  0.02), a finding
statistically significant vs. both non-COPD smokers
(Pc Z 0.012, Pa Z 0.040) and non-smokers (Pc Z 0.009,
Pa < 0.001) (Fig. 2). In contrast, PHB2 levels were similar
among the three study groups (non-smokers: 0.97  0.12;
non-COPD smokers: 1.01  0.08; COPD patients:
0.95  0.13; Pc Z 0.85, Pa Z 0.69) (Fig. 2).
Western blot analysis
Western blot analysis of PHB1 verified the above results,
since PHB1 protein levels also decreased from non-
smokers to non-COPD smokers to COPD patients, and
with a similar decrease rate as mRNA levels (non-
smokers: 1.77  0.13; non-COPD smokers: 0.97  0.08;
COPD patients: 0.59  0.10, Pc Z 0.026, Pa Z 0.007)
(Fig. 2).
PHB1 expression was not associated with the
amount of smoking exposure in COPD patients
In order to determine whether the decrease in PHB1 levels
among COPD patients was only attributed to smoking, weusing SYBR Green I detection dye: (A) Amplification plots and
ples of PCR products from the two prohibitin family members
ethidium bromide. M: 100-bp DNA ladder; (D) Representative
non-COPD smokers (S) and COPD patients (COPD). b-actin was
Figure 2 mRNA and protein expression of PHB1 in the three
study groups (non-smokers, non-COPD smokers, COPD
patients). Expression levels are normalized based on the non-
smokers group. Error bars represent each category’s SEM
(standard error of the mean). Pa: adjusted p-values corrected
for age and pack-year of smoking.
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pack-years (>100) and one with smoking exposure compa-
rable to non-COPD smokers (Table 3). Both PHB1 mRNA and
protein levels were approximately even between the two
COPD sub-groups (mRNA: 0.31  0.02 vs. 0.34  0.02,
PcZ 0.40, PaZ 0.84; protein: 0.58  0.14 vs. 0.59  0.15,
Pc Z 0.97, Pa Z 0.54) and w40% decreased from PHB1
levels in non-COPD smokers (mRNA: 0.55  0.06; protein:
0.97  0.08) (Fig. 3).PHB1 expression is associated with the severity of
airflow obstruction (FEV1)
Scatter plot analysis of PHB1 expression in relation to FEV1
showed that COPD patients and non-COPD smokers form
distinct clusters, resulting in a positive association of PHB1
expression levels with FEV1 (PmRNA Z 0.004 and
Pprotein Z 0.014) (Fig. 4). In contrast, no statisticallyTable 3 Anthropometric characteristics and spirometric valu
according to smoking exposure (heavy and light smokers), versus
COPD patients
Heavy smokers (n Z 11) Light smokers (n
Age (years) 65.0  6.1 66.5  5.8
Smoking (P-Y) 112.1  10.7 52.5  16.4
FEV1 (% pred.) 62.4  17.8 54.4  9.6
FVC (% pred.) 75.4  17.7 71.1  13.3
FEV1/FVC (%) 63.0  9.2 64.9  10.4
P-Y: pack-years of smoking (mean  SD).
FEV1: forced expiratory volume in 1st second (mean  SD).
FVC: forced vital capacity (mean  SD).
a COPD heavy smokers vs. non-COPD smokers.
b COPD light smokers vs. non-COPD smokers.
c ManneWhitney U test.significant association was observed between PHB1 mRNA
or protein levels with patients’ age or years of smoking
exposure.
Discussion
In the present study, we investigated the expression of the
two human prohibitin family members, PHB1 and PHB2, in
COPD patients, non-COPD smokers and non-smokers. Given
the critical role of the prohibitin complex in mitochondrial
biogenesis and function, we aimed to evaluate the poten-
tial implication of mitochondrial integrity maintenance
mechanisms in lung epithelium damage. We were able to
demonstrate that PHB1 mRNA and protein levels decrease
at a linear rate from non-smokers to non-COPD smokers to
COPD patients, while PHB2 expression remained steady
among the three study groups. We also established that, for
COPD patients, this decrease was not related to age or
smoking intensity, but rather to the degree of airway
obstruction (FEV1). To our knowledge, this is the first study
reporting on prohibitin expression levels in the human lung
epithelium.
The model we propose for the gradual PHB1 down-
regulation is the following: Smoking increases production of
ROS that damages the mitochondrial respiratory machinery,
leading to cellular damage and the downregulation of
PHB1. In COPD, since there is an increased inflammatory
response, the production of ROS is further elevated,
damaging lung epithelial cells, impairing mitochondrial
integrity, and thus decreasing PHB1 expression to even
lower levels.
Prohibitin mitochondrial complexes are important for
the stability of the inner mitochondrial membrane, which is
essential for maintaining intracellular respiratory func-
tions. Prohibitin also acts as a chaperone of the mito-
chondrial complex I, and especially of the NADH
dehydrogenase subunits, which are important for the
NADH:ubiquinone oxidoreductase activity, a key enzymatic
activity for detoxification and metabolizing toxins and
other dangerous substances inhaled by smoking.25 When
PHB1 is downregulated, the large PHB1/PHB2 ring-shaped
transmembrane complexes cannot form, resulting in thees of COPD patients after categorization into two groups
non-COPD smokers.
Non-COPD smokers (n Z 15) P-valuec
Z 9)
59.0  12.1 0.20a 0.17b
52.5  20.8 0.001a 0.54b
85.5  14.2 0.013a 0.003b
86.1  12.7 0.16a 0.044b
78.5  4.7 0.001a 0.001b
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levels of ROS within cells, eventually leading to their death.
PHB1 downregulation among COPD patients cannot be
attributed to smoking alone, since COPD patients with
pack-years comparable to non-COPD smokers (w52py) and
COPD patients with more than 100py had approximately the
same prohibitin-1 expression. If PHB1 expression was
correlated with the amount of smoking exposure, then
COPD patients with high tobacco consumption would have
lower prohibitin-1 mRNA and protein levels than those
observed. Therefore, there are other factors that
contribute to this effect. Possibly, the inflammatory
response, greatly increased in COPD patients,4 leads to
increased ROS production and faster cellular damage than
in smokers, which could explain the difference in PHB1
expression between COPD patients and non-COPD smokers.Figure 3 Box and whisker plots depicting relative (A) mRNA
and (B) Protein expression of PHB1, according to smoking
exposure (COPD patients with high pack-years, COPD patients
with low pack-years, non-COPD smokers). The thick line near
the center of each rectangular box represents the median
value, the bottom and top edges of the box indicate the 1st
(Q1) and 3rd (Q3) quartiles, and the ends of the whiskers depict
the 10th (P10) and 90th (P90) percentiles. Pa: adjusted p-values
corrected for age and pack-year of smoking.The finding that only PHB1 was downregulated in non-
COPD smokers and COPD patients and not PHB2, is not
unexpected. Knock-out studies in cells have shown that
when either PHB1 or PHB2 is not expressed then their ring-
shaped complex is not formed.26 Therefore, loss of only one
prohibitin protein is sufficient for the disruption of the
mitochondrial respiratory machinery.
Age is also considered a risk factor for COPD, not only
due to the steady accumulation of free radicals, heavy
metals and other by-products of the metabolism within
cells, which leads to their death, but also because with age
there is a progressive air space enlargement in the lungs,
which decreases airflow.27 However, since PHB1 expression
was not statistically associated with age, the small age
difference among our study groups cannot account for the
observed PHB1 expression differences. Univariate analysis
verified that, since all statistically confirmed associations
retained their significance even after correction with age
and pack-years of smoking.
In a previous study conducted by our group on the same
samples pool, it was demonstrated that in COPD patients
there is a shift in balance in favor of pro-apoptotic mole-
cule p53 instead of the anti-apoptotic molecule bcl-2.28
PHB1 downregulation leads to increased ROS formation
and oxidative DNA damage, which directs cells to apoptosis,
explaining the increased p53 levels we observed.
Although smoking did not have a dose-dependent effect
on PHB1 expression, FEV1 was associated with low PHB1
levels. This reflects a deteriorating mitochondrial stability
as COPD progresses.
According to the GOLD guidelines, our COPD patients
were categorized as GOLD stage II. It would be interesting
to expand the study to include patients from the other
three COPD categories (GOLD stages I, III and IV), in order
to investigate the expression levels of prohibitin in those
groups, and to determine if and why there are any differ-
ences in the expression of PHB1 among the four COPD
categories.
One thing that should be taken into consideration is the
fact that tissue samples were taken from patients that
underwent lung surgery for malignant solitary nodule
removal. However, our data have not been compromised by
the inclusion of cancer cells in the analysis, since the tissue
samples that were obtained for our study were not close to
the malignant region.
A limitation of our study could be that biopsy specimens
likely compromise multiple cell types. Histological evalua-
tions conducted in previous studies by our group in the
same sample types (COPD patients and non-COPD smokers)
suggest that the most dominant cell type within the lung
epithelium of smokers and COPD patients is type II pneu-
mocytes, along with a substantial number of alveolar
macrophages.28,29 Whether our results reflect mitochon-
drial changes within pneumocytes or macrophages cannot
be determined without performing tissue laser
microdissection.
In conclusion, our study revealed decreased PHB1 levels
in non-COPD smokers and especially in COPD patients,
reflecting a reduced mitochondrial stability that possibly
results in decreased antioxidant capacity, especially in the
mitochondria of COPD patients. Further studies are needed
to verify and expand the findings reported here.
Figure 4 PHB1 mRNA (A) and protein expression (B) In relation to FEV1 in non-COPD smokers (blue) and COPD patients (red). (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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